Thursday, 2 February 2012

COUNTESS OF MAR QUESTIONS IN THE HOUSE OF LORDS - LYME DISEASE

The Countess of Mar who has for some time represented and supported the ME/CFS patients has recently taken an interest in helping patients with Lyme Disease.

Questions in the House of Lords.
Q. To ask Her Majesty's Government whether the Lyme Unit at the Health Protection Agency has always been fully compliant with all aspects of the Data Protection Act 1998, particularly with respect to retention of patient information, using patient information for purposes for which it was not originally intended and passing patient information to third parties without consent from the patient.[HL13893]


A. The Parliamentary Under-Secretary of State, Department of Health (Earl Howe): I am informed that the Health Protection Agency and its Lyme Borreliosis Reference Laboratory complies with all aspects of the Data Protection Act 1998.

Asked by The Countess of Mar

To ask Her Majesty's Government whether, in view of the statement on the Medicines and Healthcare products Regulatory Agency website that their decisions 

7 Dec 2011 : Column WA173

will be "based on robust science" and "fact-based judgments to ensure that the benefits to patients and the public justify the risks" of new scientific research, they have conducted a recent risk assessment of the ELISA test for Lyme disease.[HL13895]

A.Earl Howe: We are advised by the Medicines and Healthcare products Regulatory Agency (MHRA) that manufacturers of in vitro diagnostic devices such as the enzyme-linked immunosorbent assay test should ensure they conform to the safety, quality and performance requirements of the European Commission In Vitro Diagnostic Devices Directive before they CE mark their products and place them on the European Union and United Kingdom market. This involves setting out their performance characteristics for the test and being able to demonstrate that it performs to the accuracy level claimed for it. The MHRA has a mainly post-market surveillance and enforcement role under the directive and would investigate any problems with the use of such a test that comes to its attention. Depending upon the results of any such investigation, the MHRA has a range of legal powers open to it that include removing the device from the UK market.


Q. To ask Her Majesty's Government why the Lyme Unit of the Health Protection Agency does not publish full details of its in-house immunoblots including the name, origin and specificity data of the antigens used and the criteria used to determine whether a result is positive, together with all the evidence from the peer-reviewed literature validating those criteria.

A. Earl Howe (Parliamentary Under Secretary of State (Quality), Health; Conservative)
The Lyme Unit of the Health Protection Agency (HPA) does not use in-house produced immunoblots in the investigation of Lyme and has not done so since 2005. The HPA's Lyme borreliosis unit currently uses commercially produced and CE-marked Trinity Biotech EU Lyme western blots as supplementary (second stage) tests in the investigation of suspected Lyme borreliosis.

House of Lords: Health: Lyme Disease (25 January 2012)
Q. The Countess of Mar: To ask Her Majesty's Government whether the Lyme Unit of the Health Protection Agency regard the 41 internal antigen on the Mikrogen immunoblot as highly specific or non-specific for the detection of Lyme disease.

 A. Earl Howe (Parliamentary Under Secretary of State (Quality), Health; Conservative)
The Lyme Unit of the health protection agency (HPA) does not use Mikrogen immunoblots. The HPA currently uses commercially produced and CE-marked Trinity Biotech European Union Lyme western blots as supplementary (second stage) tests in the investigation of suspected Lyme borreliosis..

House of Lords: Health: Lyme Disease (25 January 2012)
Q. The Countess of Mar: To ask Her Majesty's Government whether Lyme disease is still being studied at Porton Down for its potential as a biological weapon.

A. Lord Astor of Hever (Parliamentary Under Secretary of State, Defence; Conservative)
Dstl (or its predecessor organisations) has not looked at the potential for Lyme disease to be used as a biological weapon and has never had a programme of research to evaluate either the causative bacteria or its potential as a weapon.




Details can be found in 'They work for you' here 





2 comments:

  1. She has a Facebook page where Lymies can thank her, if they want, for her interest and involvement in Lyme

    ReplyDelete
  2. Should have added the link to Lady Mar !

    https://www.facebook.com/?ref=logo#!/pages/Lady-Mar/120584914700574

    ReplyDelete